bioRxiv Science⌕ Search

Biology subjects

Troitskaya, L.

Publications and source records attributed to Troitskaya, L..

2 recordsLinked to original sources

Topologically engineered antibodies and Fc-fusion proteins: a new class of multifunctional therapeutic candidates for SARS-CoV-2, cancer, and other disease

Traditional Y-shaped IgG topologies restrict conventional multispecific antibodies by imposing steric constraints that hinder target binding and stability. To overcome this, we engineered tetrahedral antibodies, a multispecific class that non-covalently self-assembles via two hinge-integrated collectrin-like domains (CLDs). This non-planar, tetrapartite architecture coordinates up to six unobstructed Fab, Fc, and extracellular domains. Parallel to the clinical translation of our dual-Fc anti-CD19/CD20 tetrahedral antibody for systemic lupus erythematosus (SLE), we evaluated an anti-SARS-CoV-2 candidate that exhibited in vivo efficacy in non-human primates. Furthermore, we demonstrate functional Fc{gamma}R binding cooperativity across the dual-Fc domains of anti-CD19/CD20 tetrahedral antibodies, while introducing an interface disulfide bond into the CLD dimer increases structural stability as evidenced by effectively abolishing CLD dynamic dissociation and resolving the dissociation equilibrium into discrete, stable quaternary states. These findings establish tetrahedral architectures as a robust, translatable multispecific platform.

molecular biology↗

Mouse Antibodies with Activity Against the SARS-CoV-2 D614G and B.1.351 Variants

With the rapid spread of SARS-CoV-2 variants, including those that are resistant to antibodies authorized for emergency use, it is apparent that new antibodies may be needed to effectively protect patients against more severe disease. Differences between the murine and human antibody repertoires may allow for the isolation of murine monoclonal antibodies that recognize a different or broader range of SARS-CoV-2 variants than the human antibodies that have been characterized so far. We describe mouse antibodies B13 and O24 that demonstrate neutralizing potency against SARS-CoV-2 Wuhan (D614G) and B.1.351 variants. Such murine antibodies may have advantages in protecting against severe symptoms when individuals are exposed to new SARS-CoV-2 variants.

molecular biology↗